Intellia Therapeutics Inc (NTLA) - News Archive

Hereditary angioedema (HAE) is a rare genetic condition characterized by recurrent episodes of potentially life-threatening swelling attacks. Current treatment options for HAE are limited and often inadequate, highlight...

Intellia Therapeutics, a renowned clinical-stage gene editing company, has recently commenced the global pivotal, Phase 3 MAGNITUDE trial of their investigational therapy, NTLA-2001. This single-dose, in vivo CRISPR-bas...

Intellia Therapeutics and ReCode Therapeutics Collaborate to Develop Groundbreaking Gene Editing Therapies for Cystic FibrosisIntellia Therapeutics, a prominent gene editing company, and ReCode Therapeutics, a genetic m...

Gene Editing Therapy Shows Promising Results in Hereditary Angioedema Patients: A Breakthrough Publication in The field of gene editing has witnessed a significant revolution in recent years, with the development of clu...